Three-Dose Pfizer Vaccine Spurs Strong Response in Youngest Children
A three-dose regimen of its COVID-19 vaccine appears to provoke a strong immune response in patients aged 6 months to 5 years.
A three-dose regimen of its COVID-19 vaccine appears to provoke a strong immune response in patients aged 6 months to 5 years.
Researchers sought to examine the demographic and clinical characteristics of patients who were infected with COVID-19 and developed PASC.
The Pfizer-BioNTech COVID-19 vaccine contributed to substantial public health impact and vaccine-preventable cost savings in the first year of its U.S. rollout.
Death or readmission after discharge from a COVID-19 hospitalization occurs in about 1 in 9 patients.
Patients diagnosed with cancer more than one year ago and those not receiving active treatment are not at heightened risk for worse COVID-19 outcomes than patients without cancer.
For adults hospitalized with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, encephalopathy at admission is the most common serious neurologic manifestation, all of which are associated with worse outcomes.
Researchers reported on the severity of COVID-19 outcomes in patients with psoriatic disease, using data from the WARCOV study.
An online breathing and well-being program can improve the mental health component of health-related quality of life (HRQoL) in long COVID.
Almost 30% of hospitalized patients and high-risk outpatients with COVID-19 develop postacute sequelae of severe acute respiratory syndrome coronavirus 2 (PASC).
A new omicron subvariant called BA.4 appears to be driving a sharp rise in COVID-19 cases in South Africa.